Effects of Traditional Chinese Medicine on AECOPD Patients

Henan University of Traditional Chinese Medicine378 enrolled

Overview

This is a multi-center, randomized, double-blind, controlled trial to compare the efficacy of two therapies for patients with AECOPD. 378 subjects will be randomly assigned to one therapies (conventional drug, and the combination of conventional drug and TCM) for 14 days treatment. After the treatment period, subjects in two arms will be followed up for 4 weeks. The primary outcomes will include COPD Assessment Test (CAT), and secondary outcomes include treatment failure rate, treatment success rate, hospitalization time, hospital admission rate, endotracheal intubation rate, mortality and quality of life (COPD-PRO, SF-36).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

378

Conditions

Pulmonary Disease, Chronic Obstructive Acute Exacerbation Medicine, Chinese Traditional

Interventions

TCM and conventional drugDRUG

All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD. The Experimental group will receive TCM according to the TCM syndrome. Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days. Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days. Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days.

TCM placebo and conventional drugDRUG

All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD. The control group will receive TCM placebo according to the TCM syndrome. Placebo Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days. Placebo Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days. Placebo Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days.

Eligibility

Sex: ALLMin age: 40 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * A confirmed diagnosis of moderate to very severe AECOPD * Age between 40 and 80 years * Syndrome differentiation meets criteria of syndrome of external cold and internal fluid,syndrome of phlegm-heat congesting lung,or syndrome of phlegm-damp amassing in lung * Without participations in other interventional trials in the previous one month * With the informed consent signed Exclusion Criteria: * Pregnant and lactating women * Dementia, mental disorders and reluctant partners * Complicated with heart failure (NYHA Class IV), or Serious cardiac arrhythmias, or unstable hemodynamics * Current respiratory disorders other than COPD (e.g., bronchiectasis, active tuberculosis, pneumothorax, Pleural effusion, pulmonary thromboembolic, or Neuromuscular diseases affect respiratory movement function) * Combined tumor * Treated outside the hospital for more than 7 days * Need to carry out invasive mechanical ventilation respiratory failure * Complicated with serious hepatic and renal diseases (liver cirrhosis, portal hypertension, bleeding of varicose veins, dialysis, or renal transplantation) * Bedridden for various reasons * Allergic to the used medicine

Outcomes

Primary Outcomes

COPD Assessment Test(CAT)

Using COPD Assessment Test ( CAT) to asses the impact of AECOPD on a person's life, and how this changes over time.

Time frame: Change from baseline CAT score at day 0, 14 of the treatment phase, at day 14, 28 of the follow-up phase.

Secondary Outcomes

Treatment failure rate

Time frame: The numbers of treatment failure at day 14 of the treatment phase.

Treatment success rate

Time frame: The numbers of treatment success at day 14 of the treatment phase.

Length of hospital stays

length hospital stays will be recorded.

Time frame: The length hospital stays in 14 Days of the treatment phase

Readmission due to AECOPD

Readmission due to AECOPD will be recorded.

Time frame: The numbers of readmission due to AECOPD in 28 Days of the followup phase.

Intubation rate

Intubation will be recorded.

Time frame: The numbers of intubation at day 4,7,10，14 of the treatment phase, at day 14, 28 of the follow-up phase.

Mortality

Time frame: The numbers of mortality at day 14 of the treatment phase and day 28 of the follow-up phase.

Dyspnea

Using modified Medical Research Council (mMRC) to asses the dyspnea of COPD, and how this changes over time.

Time frame: Change from Baseline in the mMRC at day 0, 4, 7, 10,14 of the treatment phase, at day 14, 28 of the follow-up phase.

SF-36

Using the MOS item short from health survey (SF-36) to asses the impact of COPD on a person's life, and how this changes over time.

Time frame: Change from Baseline in the SF-36 at day 0,14 of the treatment phase, at day 14, 28 of the follow-up phase.

COPD-PRO

Using the COPD patient reported outcome scale (COPD-PRO) to asses the impact of COPD on a person's life, and how this changes over time.

Time frame: Change from Baseline in the COPD-PRO at day 0,14 of the treatment phase, at day 14, 28 of the follow-up phase.